Categories for Trade

USTR Releases Much-Anticipated 301 Report, Fails to Reinstate Exemptions Process

SOCMA strongly supports the introduction of the Miscellaneous Tariff Bill Reform Act by Trade Subcommittee Chair Adrian Smith (R-NE) with nearly 20 cosponsors, including 17 Ways and Means Committee members. SOCMA has been advocating for MTB reauthorization since 2020 and focused on educating congressional offices on the Ways and Means Committee. 

May 16, 2024

SOCMA Praises Legislation to Reauthorize Key Trade Program 

SOCMA strongly supports the introduction of the Miscellaneous Tariff Bill Reform Act by Trade Subcommittee Chair Adrian Smith (R-NE) with nearly 20 cosponsors, including 17 Ways and Means Committee members. SOCMA has been advocating for MTB reauthorization since 2020 and focused on educating congressional offices on the Ways and Means Committee. 

May 15, 2024

SOCMA Government Relations Update: Trade & Supply Chain

Last week, the House Ways and Means and Senate Finance Committees held hearings on “The Administration’s 2024 Trade Priorities”, where US Trade Representative Katherine Tai appeared as a witness to discuss the President’s stances on current and potential trade programs.

April 25, 2024

SOCMA Statement on USTR Court Brief and 301 Exclusions

The Society of Chemical Manufacturers and Affiliates (SOCMA) Vice President, Legal and Government Relations, Robert F. Helminiak released a statement today explaining that the Office of the United States Trade Representative (USTR) does not have an adequate exemption or exclusion process for Section 301 China Tariffs.

August 12, 2022

SOCMA Launches Policy Webinar Series in April

As the specialty chemicals industry anticipates new policy and regulations coming under the Biden Administration, the Society of Chemical Manufacturers & Affiliates (SOCMA) is hosting its Policy Webinar Series throughout April to focus these key topics that are crucial to its membership and the value chain.

March 30, 2021

SOCMA Seeks Member Input on Chinese-origin Medical-Care Products

The Office of the U.S. Trade Representative (USTR) has announced that USTR is requesting public comments by June 25, 2020 on further modifications to remove Section 301 duties from additional Chinese-origin medical-care products, including pharmaceuticals and chemicals to make pharmaceuticals. SOCMA will submit comments to the docket and as such, requests input from members via the SOCMA 301 COVID-19 Data Sheet (page 3) for inclusion in SOCMA 301 COVID-19 Comments.

March 31, 2020